Eric Pauwels
Net Worth

Last updated:

What is Eric Pauwels net worth?

The estimated net worth of Mr. Eric Pauwels is at least $9,771,340 as of 17 Apr 2024. He owns shares worth $3,324,452 as insider, has earned $1,571,188 from insider trading and has received compensation worth at least $4,875,700 in PTC Therapeutics, Inc..

What is the salary of Eric Pauwels?

Mr. Eric Pauwels salary is $975,140 per year as Chief Bus. Officer in PTC Therapeutics, Inc..

How old is Eric Pauwels?

Mr. Eric Pauwels is 63 years old, born in 1962.

What stocks does Eric Pauwels currently own?

As insider, Mr. Eric Pauwels owns shares in one company:

Company Title Shares Price per share Total value
PTC Therapeutics, Inc. (PTCT) Chief Bus. Officer 67,694 $49.11 $3,324,452

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Eric Pauwels insider trading

PTC Therapeutics, Inc.

Mr. Eric Pauwels has made 27 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 787 units of PTCT stock worth $19,781 on 17 Apr 2024.

The largest trade he's ever made was exercising 7,248 units of PTCT stock on 17 May 2023. As of 17 Apr 2024 he still owns at least 67,694 units of PTCT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 787 $25.14 $19,781
Sale
Common Stock 366 $27.25 $9,974
Sale
Common Stock 2,065 $29.02 $59,916
Sale
Common Stock 1,569 $28.64 $44,936
Sale
Common Stock 1,913 $58.98 $112,825
Sale
Common Stock 100 $59.66 $5,966
Sale
Common Stock 6,403 $58.96 $377,489
Sale
Common Stock 788 $58.71 $46,267
Sale
Common Stock 800 $58.52 $46,814
Sale
Common Stock 7,248 $58.5 $424,008
Sale
Common Stock 732 $52.04 $38,096
Sale
Common Stock 375 $45.63 $17,111
Sale
Common Stock 359 $47.45 $17,035
Sale
Common Stock 571 $44.36 $25,330
Sale
Common Stock 663 $42.93 $28,465
Sale
Common Stock 858 $41.66 $35,741
Sale
Common Stock 822 $42.52 $34,947
Sale
Common Stock 367 $40 $14,681
Sale
Common Stock 359 $39.31 $14,114
Sale
Common Stock 866 $38.53 $33,363
Sale
Common Stock 806 $41.16 $33,177
Sale
Common Stock 786 $48.17 $37,860
Sale
Common Stock 362 N/A N/A
Sale
Common Stock 431 $62.05 $26,745
Sale
Common Stock 1,067 $62.37 $66,549
Sale
Common Stock 1,067 N/A N/A
Sale
Common Stock 6,194 N/A N/A

PTC Therapeutics key executives

PTC Therapeutics, Inc. executives and other stock owners filed with the SEC: